Citi lowered the firm’s price target on Atara Biotherapeutics to 40c from $1.40 and keeps a Sell rating on the shares. The analyst updated the company’s model post the Q3 report. The firm cites switching the tab-cel revenue model from sales to royalties and milestones and lower cash for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATRA:
- Atara Biotherapeutics downgraded to In Line from Outperform at Evercore ISI
- Atara Biotherapeutics price target lowered to $13 from $19 at Canaccord
- Atara Biotherapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Atara Biotherapeutics downgraded to Neutral from Buy at Mizuho
- Atara Biotherapeutics trading resumes